Substituted aminopyrimidine protein kinase B (PknB) inhibitors show activity against Mycobacterium tuberculosisMore about Open Access at the Crick
Authors listTM Chapman N Bouloc RS Buxton J Chugh KEA Lougheed SA Osborne B Saxty SJ Smerdon DL Taylor D Whalley
A high-throughput screen against PknB, an essential serine-threonine protein kinase present in Mycobacterium tuberculosis (M. tuberculosis), allowed the identification of an aminoquinazoline inhibitor which was used as a starting point for SAR investigations. Although a significant improvement in enzyme affinity was achieved, the aminoquinazolines showed little or no cellular activity against M. tuberculosis. However, switching to an aminopyrimidine core scaffold and the introduction of a basic amine side chain afforded compounds with nanomolar enzyme binding affinity and micromolar minimum inhibitory concentrations against M. tuberculosis. Replacement of the pyrazole head group with pyridine then allowed equipotent compounds with improved selectivity against a human kinase panel to be obtained.